Invivyd, Inc. (IVVD)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 25 | 53 | 58 | 60 |
| Operating profit | $m | -56 | -113 | ||||||
| Net profit | $m | -112 | -227 | -241 | -199 | -170 | -52 | -107 | -90 |
| EPS reported | $ | -0.30 | -0.39 | ||||||
| Operating cashflow per share | $ | -0.34 | -0.34 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.34 | -0.34 | ||||||
| Free cash flow | $m | -58 | -110 | ||||||
| Net debt | $m | -227 | -160 | ||||||
| Book value equity | $m | 242 | 181 | ||||||
| Book value per share | $ | 1.40 | 0.57 | ||||||
| Number of shares | m | 172.21 | 320.44 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.76 | 2.35 | ||||||
| P/S LTM | x | 7.96 | 7.29 | ||||||
| P/FCF LTM | x | -7.30 | -3.88 | ||||||
| EV/EBITDA LTM | x | -3.99 | -1.87 | ||||||
| EV/Sales LTM | x | 3.77 | 1.04 | ||||||
| Earnings Yield LTM | % | -12.34% | -46.46% | ||||||
| FCF Yield | % | -13.70% | -25.78% | ||||||
| Quality | |||||||||
| ROE | % | -21.73% | -59.73% | ||||||
| ROIC | % | -22.77% | -59.39% | ||||||
| Operating margin | % | -1.04% | -1.93% | ||||||
| Gross margin | % | +92.99% | +91.35% | ||||||
| FCF/Sales | % | -109.10% | -187.88% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +110.47% | +129.93% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -23.37 | -13.07 | ||||||
| Net Debt/EBITDA | x | 4.45 | 1.41 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | +3.95% | ||||||
| Net debt/Equity | x | -0.94 | -0.88 | ||||||
| Gross debt/equity | x | 0.01 | 0.05 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free